WB, IHC-Bond, IHC-P, IF-IC, FC-FP
H M R Mk
Endogenous
85
Rabbit IgG
#O75330
3161
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| IHC Leica Bond | 1:50 - 1:200 |
| Immunohistochemistry (Paraffin) | 1:50 - 1:200 |
| Immunofluorescence (Immunocytochemistry) | 1:50 - 1:200 |
| Flow Cytometry (Fixed/Permeabilized) | 1:100 - 1:200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human RHAMM/CD168 protein. The antigenic peptide spans a region that is 100% conserved among the four isoforms of RHAMM/CD168 reported in Uniprot.
Background
Receptor for Hyaluronic acid-Mediated Motility (RHAMM, known also as CD168 or HMMR) was first identified as a putative receptor for hyaluronic acid (HA) that modulated HA-mediated cell motility (1). RHAMM/CD168 is functionally similar to the HA receptor CD44; however in contrast to CD44, RHAMM/CD168 does not contain a transmembrane domain or a signal peptide leader sequence, and so is not targeted exclusively to the cell membrane (1). RHAMM/CD168 has multiple isoforms; some are reportedly exported to the cell membrane in response to signaling by growth factors and cytokines (e.g., TGF-β) (2, 3), whereas others have been implicated in intracellular functions including mitotic spindle regulation (4). Cell surface RHAMM/CD168 is localized to membrane ruffles, consistent with proteins that regulate cell motility (1). Numerous research studies have reported that the expression of RHAMM/CD168 is positively associated with cancer cell growth, motility and/or metastasis (5-7), in addition to HA-mediated inflammation (8), suggesting the potential for therapeutic approaches that target HA-receptor mediated signaling (9,10).
- Hardwick, C. et al. (1992) J Cell Biol 117, 1343-50.
- Samuel, S.K. et al. (1993) J Cell Biol 123, 749-58.
- Naor, D. (2016) Front Immunol 7, 39.
- Tolg, C. et al. (2010) J Biol Chem 285, 26461-74.
- Mele, V. et al. (2017) Oncotarget 8, 70617-29.
- Morera, D.S. et al. (2017) Br J Cancer 117, 1507-17.
- Wang, D. et al. (2016) Oncotarget 7, 39957-69.
- Hauser-Kawaguchi, A. et al. (2018) Matrix Biol 78-79, 346-56.
- Wong, K.M. et al. (2017) Curr Oncol Rep 19, 47.
- Yang, C. et al. (2017) Theranostics 7, 1719-34.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IHC-Bond: IHC Leica Bond IHC-P: Immunohistochemistry (Paraffin) IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
